Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 5, 2003, Pages 877-880

  Bråthe, Anders ^a   Gundersen, Lise Lotte ^a   Nissen Meyer, Jon ^a   Rise, Frode ^a   Spilsberg, Bjørn ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

6 ALKENYLPURINE; 6 ALKYNYLPURINE; ALKYNE; FLUDARABINE; MERCAPTOPURINE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG ACTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; PLANT GROWTH;

EID: 0037430585     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00011-8     Document Type: Article

References (33)

1. Bråthe A., Andresen G., Gundersen L.-L., Malterud K.E., Rise F. Bioorg. Med. Chem. 10:2002;1581.
2. Sendobry S.M., Cornicelli J.A., Welch K., Bocan T., Tait B., Trivedi B.K., Colbry N., Dyer R.D., Feinmark S.J., Daughterty A. Br. J. Pharmacol. 120:1997;1199.
3. Bocan T.M.A., Rosebury W.S., Mueller S.B., Kuchera S., Welch K., Daugtherty A., Cornicelli J.A. Atherosclerosis. 136:1998;203.
4. Cyrus T., Witztum J.L., Rader D.J., Tanirala R., Fazio S., Linton M.F., Funk C.D. J. Clin. Invest. 103:1999;1597.
5. Halliwell B. Drugs. 42:1991;569.
6. Halliwell B. Drugs Aging. 18:2001;685.
7. Rice-Evans C.A., Diplock A.T. Free Radical Biol. Med. 15:1993;77.
8. Bråthe A., Gundersen L.-L., Rise F., Eriksen A.B., Vollsnes A.V., Wang L. Tetrahedron. 55:1999;211.
9. Andresen G., Gundersen L.-L., Nissen-Meyer J., Rise F., Spilsberg B. Bioorg. Med. Chem. Lett. 12:2002;567.
10. (a) Hocek M., Holy A., Votruba I., Dvorakova H. J. Med. Chem. 43:2000;1817.
11. (b) Hocek M., Holy A., Votruba I., Dvorakova H. Collect. Czech. Chem. Commun. 67:2001;483.
12. (c) Gundersen L.-L., Nissen-Meyer J., Spilsberg B. J. Med. Chem. 45:2002;1383.
13. Hocek M., Votruba I. Bioorg. Med. Chem. Lett. 12:2002;1055.
14. Compounds 2a, 2b and 2j were prepared according to ref 1, and 2h, 2i, 4a, 4c, 4i-4s were prepared as described in ref 8.
15. For synthesis of 2d and 4f see: Bakkestuen A.K., Gundersen L.-L., Langli G., Liu F., Nolsøe J.M.J. Bioorg. Med. Chem. Lett. 10:2000;1207.
16. For synthesis of 2e, 4e and 4g see: Langli G., Gundersen L.-L., Rise F. Tetrahedron. 52:1996;5625.
17. For synthesis of 2c, see: Nolsøe J.M.J., Gundersen L.-L., Rise F. Acta Chem. Scand. 53:1999;366.
18. For synthesis of 3a, 3b, 4d see Gundersen L.-L., Bakkestuen A.K., Aasen A.J., Øverås H., Rise F. Tetrahedron. 50:1994;9743.
19. For synthesis of 4b see Gundersen L.-L. Tetrahedron Lett. 35:1994;3155.
20. Compound 2g was prepared essentially as described before: Koyama S., Kumazawa Z., Kashimura N. Nucl. Acids Res., Symp. Ser. 11:1982;41.
21. 4O4 355.1400.
22. Lozzio C.B., Lozzio B.B. Blood. 45:1975;321.
23. 2.
24. 3H]-thymidine incorporation for the K-562 cells used (results not shown).
25. Nagatsugi F., Uemura K., Nakashima S., Maeda M., Sasaki S. Tetrahedron Lett. 36:1995;421.
26. Nagatsugi F., Uemura K., Nakashima S., Maeda M., Sasaki S. Tetrahedron. 53:1997;3035.
27. Øverås A.T., Bakkestuen A.K., Gundersen L.-L., Rise F. Acta Chem. Scand. 51:1997;1116.
28. Montgomery J.A., Hewson K. J. Med. Chem. 11:1968;48.
29. (b) Van Aerschot A.A., Mamos P., Weyns N., Ikeda S., De Clercq E., Herdewijn P.A. J. Med. Chem. 36:1993;2938.
30. (c) Hassan A.E.A., Abou-Elkair R.A.I., Montgomery J.A., Secrist J.A. Nucleosides Nucleotides Nucleic Acids. 19:2000;1123.
31. (c) Hocek M., Holy A., Votruba I., Dvorakova H. Collect. Czech. Chem. Commun. 65:2000;1683.
32. (e) Hocek M., Holy A., Dvorakova H. Collect. Czech. Chem. Commun. 67:2002;325.
33. Øverås A.T., Gundersen L.-L., Rise F. Tetrahedron. 53:1997;1777.